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24 Oral PresentationsSCT. Median whole blood donor chimerism on days 30, 60, 100, and
180 was 95%(9–100), 90%(61–99), 90%(60–99), and 91%(88–98),
respectively. Median CD71 chimerism on days 30, 60, 100, and
180 was 98%(17–99), 88%(1–99), 90%(71–99), and 92%(80–96), re-
spectively. Hb electrophoresis demonstrated median %HbS levels of
1.160.1, 060.1, and 1.060.1 on days 30, 60, and 100 respectively.
Of evaluable patients, Grades II-IV acute GVHD was seen in
4/13(30.7%) patients and chronic extensive GVHD was seen in 1/
9 (11.1%) patients. Three patients developed CMV pre-engraftment
(CMV pneumonitis (n 5 2), CMV viremia (n 5 1)) and one devel-
oped CMV viremia post engraftment. OS is 100% (longest follow
up 1491 days). In summary, RIC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of
sustained mixed donor chimerism.57
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Genetic modification of T cells to express a chimeric antigen re-
ceptor (CAR) is a promising therapy for the treatment of malignan-
cies and we have implemented a clinical trial infusing T cells which
express CAR after electro-transfer of DNA plasmid vector. However,
generating CAR1 T cells for diseases that are rapidly progressing,
such as relapsed pediatric B-lineage acute lymphoblastic leukemia
(B-ALL) after allogeneic hematopoietic stem-cell transplantation
(HSCT) is challenging. To meet this challenge we have combined
bioengineering with immunotherapy to develop a new platform tech-
nology for gene transfer of CAR into T cells. This approach side-
steps the problem associated with conventional viral and non-viral
methods for gene transfer that rely on integrating expression vectors
which are typically laborious (sometimes taking weeks of cell-culture
to generate clinically-significant cell doses) and expensive. What is
needed, and is provided here, is a cost-efficient approach to the
genetic transfer of large numbers of minimally manipulated T cells
that can be rapidly modified ex vivo and immediately infused for in
vivo therapy. We have fabricated and tested a series of high through-
put micro-electroporation devices (HitMeds). The initial multi-
electrode HitMed was designed to investigate the electroporation pa-
rameters in a channel with single-cell flow dynamics. Subsequently,
a ‘‘wafer-type’’ HitMed was developed to handle a large number of
T cells in short time. The area of the electrodes of wafer-HitMed is
3,600 mm2 (commercial cuvette: 144 mm2) with a gap, initially set
at 400 mm, but which can be easily changed to enable large numbers
of T cells to be synchronously electroporated. We have adapted the
wafer-HitMed to the electro-transfer of mRNA to avoid genotoxicity
associated with integration. The data in Table 1 demonstrates that
a CD19-specific CAR coded from introduced mRNA is efficiently
electro-transferred into T cells. The expression of CAR transgene
was 80% 24 hours after electroporation as determined by flow cytom-
etry analysis. We recognize that the CAR expression is transient, but
this can be compensated through repeated infusions of the CAR1 T
cells. We foresee the implementation of micro-electroporators to
generate CAR1 T cells for immediate infusion to achieve B-ALL
disease control. As needed, these initial infusions may be followed by
adoptive immunotherapy of T cells with stable CAR expression for
disease eradiation and prevention.Expression of CAR and GFP (%)
Cuvette Cuvette HitMed HitMedCAR GFP CAR GFP
DNA 31.05 44.04 23.95 36.74
mRNA 78.39 82.48 80.02 90.6758
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Objective: After paediatric haematopoietic stem cell transplanta-
tion (HSCT) adenovirus (HAdV) infection is a severe complication
with high morbidity and mortality rate. By intensive surveillance
patients at high risk for developing HAdV disease can early be iden-
tified in order to start preemptive therapy with antiviral medication
in an early stage.
Methods: In a prospective study, we determined the predictive
value of HAdV DNA positivity in nasopharyngeal fluid preceding
HSCT to identify patients at risk for a plasma HAdV reactivation af-
ter HSCT. We weekly monitored Adenovirus DNA loads in plasma
after HSCT. HAdV reactivation was defined as plasma viral DNA
load .1000cp/mL. Secondly, the association between plasma
HAdV reactivation and alloreactive disease (Graft-versus-Host
disease and/or idiopathic pulmonary syndrome) was analyzed, using
Cox proportional hazard models.
Results: A total of 62 patients were included: 37 (60%) recipients
received bone marrow (17/37, 46%, matched family donor) or
unrelated peripheral blood stem cells while 25 (40%) recipients re-
ceived unrelated cord blood stem cells. 42/62 (68%) recipients re-
ceived HLA-matched stem cells (for BM/PBSC high resolution
typing, for CB intermediate: HLA-A and B on low and HLA-DR
on high resolution). All patients received myeloablative conditioning
and standardized Graft-versus-host disease prophylaxis. The median
follow-up time was 47 (5–150) weeks. Prior to HSCT, HAdV DNA
could be detected in nasopharyngeal fluid of 8/62 patients (13%). In
all these patients (100%), plasma HAdV reactivation occurred
during isolated hospitalization at a median time of 12.5 days (range
5–72 days) after HSCT. Additionally, 11 (18%) patients developed
plasma HAdV reactivation at a median time of 40 (14–160) days after
HSCT. In multivariate analysis HAdV DNA positivity in nasopha-
ryngeal fluid was the only significant predictor for plasma HAdV
reactivation after HSCT (HR 9.7; 95%CI 3.4–27.4; p 5 0.000).
Plasma HAdV reactivation was a predictor for allo-reactive disease
(HR 2.6; 95% CI 1.2–5.4; p 5 0.013).
Conclusions: HAdV positivity in nasopharyngeal fluid pre-
HSCT is a very strong predictor for the development of plasma
HAdV reactivation after HSCT. Prevention or early pre-emptive
treatment with antiviral therapy might contribute to prevent
HAdV disease and / or HSCT associated problems after HSCT.59
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UCBT offers a cure for thalassemia and has advantages as a stem
cell source because of the less stringent requirements for an HLA
match between donors and recipients. Previous reports of UCBT
for thalassemia have yielded transplant related mortality (TRM) that
appeared high. It is known that pre-freeze total nucleated cell
(TNC) dose is critical for UCBT. With strategies that maximize
TNC dose – using non-red cell reduced but plasma depleted (PD)
CB, no post-thaw wash (NW), and double cord transplantation
(DCT) when necessary – we have achieved promising results with
UCBT in young patients with transfusion-dependent b-thalassemia.
Between 10/2003 and 5/2008, 39 CB products were infused after
Bu/Cy/ATG myeloablation into 30 pediatric thalassemia major pa-
tients (9 DCT) using NW PD CB exclusively. Patient status: 21 Pe-
saro class-1, 8 class-2, and 2 unknown. Median age was 5 years
(range 1–14 years) with a median weight of 18 kg (range 11–37 kg).
The data was audited by the transplant center (TC) and on-site by
